FDA Updates Human Factors Guidance for Medical Devices in 2026
The US Food and Drug Administration (FDA) has finalized its updated FDA Human Factors Guidance for Medical Devices, introducing additional clarity on human factors (HF) information required in premarket submissions. Published on 28 May 2026, the guidance includes new risk-based considerations, expanded submission examples, and updated recommendations for manufacturers preparing FDA medical device applications.
The updated FDA Human Factors Guidance for Medical Devices applies to:
- 510(k) premarket notifications
- Premarket Approval (PMA) applications
- De Novo requests
Regulatory Excellence for Global Medical Device Markets
Key Changes in FDA Human Factors Guidance for Medical Devices
The finalized FDA Human Factors Guidance for Medical Devices expands upon the draft guidance released in 2022 and introduces several important updates for manufacturers.
FDA added new decision points related to:
- Intended use environment
- Device user interface complexity
- Existing risk control measures
- Interface history of the device
- Use-related risk analysis (URRA)
According to FDA, manufacturers should carefully evaluate these factors when determining whether human factors validation testing data should be included in their submissions.
FDA Clarifies Human Factors Expectations for Modified Medical Devices
The appendices cover:
- HF Submission Category 1
- HF Submission Category 2
- HF Submission Category 3
These additions are intended to help manufacturers prepare more organized and FDA-compliant documentation.
FDA Provides Clarification for Combination Products
FDA clarified that combination products may involve additional usability risks and human factors considerations that are not fully addressed in the FDA Human Factors Guidance for Medical Devices.
The agency encouraged manufacturers to contact the appropriate FDA review division for product-specific recommendations related to combination products.
FDA also emphasized that this guidance does not replace existing device-specific guidances or regulatory requirements.
FDA Allows Transition Period for Industry Compliance
FDA acknowledged that manufacturers and regulators may need time to adapt to the updated FDA Human Factors Guidance for Medical Devices.
According to the agency, submissions currently under review, as well as submissions received before August 1, 2026, may not yet include all newly recommended information outlined in the final guidance.
However, FDA confirmed that it will review any additional human factors information voluntarily submitted during this transition period.
Why FDA Human Factors Guidance for Medical Devices Is Important?
FDA Human Factors Guidance for Medical Devices plays a critical role in improving device usability, reducing use-related risks, and enhancing patient safety. The updated guidance is expected to help manufacturers strengthen usability engineering processes and improve regulatory submission quality.
As FDA continues to increase focus on usability and risk management, manufacturers should review the updated guidance carefully and align their documentation strategies with current regulatory expectations.
How Can Operon Strategist Help with FDA Human Factors Guidance for Medical Devices?
Operon Strategist supports medical device manufacturers in preparing regulatory documentation aligned with evolving FDA requirements, including FDA Human Factors Guidance for Medical Devices. Our team assists companies in identifying use-related risks, preparing usability engineering documentation, supporting human factors validation activities, and aligning submissions with FDA expectations for 510(k), PMA, and De Novo applications.
From risk analysis support to regulatory documentation strategy, Operon Strategist helps manufacturers improve compliance readiness while addressing device usability and patient safety requirements throughout the product development lifecycle.